PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Income Statement
NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 59.76M | 53.40M | 65.49M | 47.64M | 38.35M | |||
| Cost Of Goods | 29.90M | 24.32M | 22.98M | 19.59M | 16.35M | |||
| Gross Profit | 29.87M | 29.08M | 42.51M | 28.05M | 22.00M | |||
| Operating Expenses | 25.24M | 25.16M | 32.05M | 41.06M | 42.46M | |||
| Research and Development | 13.56M | 12.97M | 17.09M | 29.35M | 29.73M | |||
| Selling, General, and Administrative Expenses | 11.68M | 12.19M | 14.96M | 11.71M | 12.73M | |||
| Operating Income | 4.63M | 3.92M | 10.46M | -13.01M | -20.46M | |||
| Interest Income/Expense | 527.00K | 237.00K | -1.51M | -1.31M | -5.03M | |||
| Other Income/Expense | N/A | N/A | -379.00K | -70.00K | -2.09M | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | 5.16M | 4.15M | 8.57M | -14.40M | -27.58M | |||
| Income Tax | 1.25M | 1.22M | 254.00K | 530.00K | N/A | |||
| Net Income | 3.91M | 2.93M | 8.31M | -14.93M | -27.58M | |||
| EBITDA | 5.96M | 5.22M | 11.65M | -11.92M | -19.34M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.02 | 0.04 | 0.10 | -0.31 | -0.62 | |||
| Non GAAP EPS | 0.04 | 0.03 | 0.05 | N/A | -0.63 | |||
| Statistics | ||||||||
| Gross Profit Margin | 49.97% | 54.46% | 64.91% | 58.88% | 57.37% | |||
| Profit Margin | 6.54% | 5.49% | 12.69% | -31.34% | -71.92% | |||
| Operating Profit Margin | 7.74% | 7.34% | 15.97% | -27.31% | -53.35% | |||
All data in USD